Related Experiment Video
Updated: Mar 9, 2026
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Matrine derivative YF-18 inhibits lung cancer cell proliferation and migration through down-regulating Skp2
Lichuan Wu1, Guizhen Wang2, Jinrui Wei3
1School of Chemistry and Chemical Engineering, Guangxi University, Nanning, Guangxi, PR China.
Abstract:
Lung cancer is the leading cause of cancer related death which needs novel drugs to improve patient outcomes. In this study, we examined the ability of YF-18, a novel matrine derivative to inhibit the growth and migration of lung cancer cells. By cell cycle analysis, wound healing and transwell assays, we found that YF-18 induced G2/M cell cycle arrest and inhibited migration of lung cancer cells in a dose-dependent manner. Further results indicated that YF-18 inhibited cell proliferation and migration through down-regulating Skp2 and up-regulating its substrates, p27 and E-cadherin. Moreover, YF-18 inhibited A549-luciferase cell xenograft tumor growth in a dose-dependent manner. The findings indicate that YF-18 bears therapeutic potentials for lung cancer.
Insights
YF-18, a novel matrine derivative, effectively inhibits lung cancer cell growth and migration. This compound shows therapeutic potential by inducing cell cycle arrest and down-regulating specific proteins involved in cancer progression.
Area of Science:
- Oncology
- Pharmacology
Background:
- Lung cancer remains a leading cause of cancer-related mortality globally.
- Novel therapeutic agents are urgently needed to improve patient outcomes.
- Matrine derivatives are being explored for their anti-cancer properties.
Purpose of the Study:
- To investigate the anti-cancer effects of YF-18, a novel matrine derivative, on lung cancer.
- To determine the mechanisms by which YF-18 affects lung cancer cell proliferation, migration, and cell cycle progression.
Main Methods:
- Cell cycle analysis was performed to assess cell cycle distribution.
- Wound healing and Transwell assays were used to evaluate cell migration.
- Western blotting was employed to analyze the expression of Skp2, p27, and E-cadherin.
- In vivo studies involved monitoring the growth of A549-luciferase cell xenografts.
Main Results:
- YF-18 induced a dose-dependent G2/M cell cycle arrest in lung cancer cells.
- YF-18 significantly inhibited lung cancer cell proliferation and migration.
- The compound down-regulated Skp2 expression while up-regulating p27 and E-cadherin.
- YF-18 demonstrated a dose-dependent inhibition of xenograft tumor growth in vivo.
Conclusions:
- YF-18 exhibits significant anti-cancer activity against lung cancer cells.
- The therapeutic effects of YF-18 are mediated through modulation of Skp2, p27, and E-cadherin.
- YF-18 presents promising therapeutic potential for the treatment of lung cancer.
